GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of small molecule, glycobiology-based therapies for a broad range of indications today announced that data from in vitro and in vivo preclinical studies of GMI-1070 in models of multiple myeloma will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).
